Re: FDA approves Pfizer nerve pain drug ~ Lyrica
From: Sharon Hope (shope_at_anet.net)
Date: 01/05/05
- Previous message: Sharon Hope: "Re: FDA approves Pfizer nerve pain drug ~ Lyrica"
- In reply to: Don Kirkman: "Re: FDA approves Pfizer nerve pain drug ~ Lyrica"
- Next in thread: listener: "Re: FDA approves Pfizer nerve pain drug ~ Lyrica"
- Reply: listener: "Re: FDA approves Pfizer nerve pain drug ~ Lyrica"
- Messages sorted by: [ date ] [ thread ]
Date: Wed, 05 Jan 2005 03:11:51 GMT
"Don Kirkman" <donkirk@covad.net> wrote in message
news:u5olt05c7dmvjo6gr58o1cc4alrvg63oja@4ax.com...
> It seems to me I heard somewhere that Sharon Hope wrote in article
> <qinCd.745407$mD.158002@attbi_s02>:
>
>>You are ignorant of the facts in this case.
>
>>Dr. Golomb does not practice at the university. Her practice is at the VA
>>Medical Center.
>
>>A renaissance woman, she is the NIH Principal Investigator for the NIH
>>Statin Study (which accepts no drug company funding), and concurrently she
>>is teaching at two universities, and a RAND researcher. She is also the
>>US
>>DOD's expert on Gulf War Syndrome.
>>
>>Her credentials are readily accessible (CV below). What are your
>>credentials?
>
> My only point had nothing to do with credentials. I may have been in
> error about the location of her principal practice, though she is an
> Assistant Professor of Medicine at the University of California-San
> Diego.
>
> To restate my point, it is not at all clear what Dr. Golomb's 15% figure
> is measuring. I didn't find it in reports of her publications or
> presentations I found in Google, and the only clear statement of that
> figure is "Dr. Golomb has found that 15 percent of statin patients
> develop some cognitive side effects.{22}" contained in a web page I
> believe you are familiar with, since it discusses your husband's case:
> http://www.mercola.com/2004/jul/24/statin_drugs.htm.
>
Thanks for mentioning it, I hadn't seen that particular web page. (But I
did see the articles they are highlighting)
> Reference 22 says in its entirety "22. Email communication, Beatrice
> Golomb, July 10, 2003."
>
> Perhaps you have a documented source for that figure?
>
We are both reading from the same source. Until her study is published,
that is what we have.
> As we were discussing almost a year ago:
>
> "'Although the patient data in the NIH study is still secret, Dr. Golomb
> says that among other patients she has seen, about 15% have developed
> some cognitive problem related to statin use. Even so, notes Dr. Golomb,
> 'there are still people who are persuaded ... that there are no
> cognitive effects from statins.'
>
> "Note that the 15% is not from the NIH study but is Dr. Golomb's
> estimate from her own practice. Also note that 15% could be three
> patients out of twenty, and that Dr. Golomb's clientele may not be
> typical, since she is associated with a university."
Now you know that her association with a university is independent of her
patient load. She does not see "patients" at the university. She treats
patients at the VA.
If she meant subjects in the study, she would likely have used that term.
Then again, she may have meant % of patient loads of doctors in general.
Hold that question for the study publication and you may get the answer. It
is a good question. Best answered correctly than through speculation.
> --
> Don
> "I do not feel obliged to believe that the same God who has endowed
> us with senses, reason, and intellect has intended us to forgo their
> use. --Galileo Galilei
- Previous message: Sharon Hope: "Re: FDA approves Pfizer nerve pain drug ~ Lyrica"
- In reply to: Don Kirkman: "Re: FDA approves Pfizer nerve pain drug ~ Lyrica"
- Next in thread: listener: "Re: FDA approves Pfizer nerve pain drug ~ Lyrica"
- Reply: listener: "Re: FDA approves Pfizer nerve pain drug ~ Lyrica"
- Messages sorted by: [ date ] [ thread ]
Relevant Pages
|